Samsung BioLogics Co Ltd
207940
Company Profile
Business description
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2024, Samsung Biologics had a total production capacity of 754,000 liters, one of the largest in the world. Its CDMO services account for 66.2% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.
Contact
125, Cheomdan-daero
Yeonsu-gu
Incheon
KORSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5,011
Stocks News & Analysis
stocks
Strong result for ASX insurer but not the new norm
Stellar first half profits but increasing competition will lower future rate increases.
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
stocks
Solid 2025 for A-REIT but development activity will weigh on 2026
Positive news for income investors as yield exceeds 5%.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,104.30 | 27.70 | 0.31% |
| CAC 40 | 7,743.00 | 33.68 | 0.44% |
| DAX 40 | 24,162.86 | 29.64 | -0.12% |
| Dow JONES (US) | 44,175.61 | 206.97 | 0.47% |
| FTSE 100 | 9,095.73 | 5.04 | -0.06% |
| HKSE | 24,844.12 | 14.70 | -0.06% |
| NASDAQ | 21,450.02 | 207.32 | 0.98% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,906.21 | 61.58 | 0.48% |
| S&P 500 | 6,389.45 | 49.45 | 0.78% |
| S&P/ASX 200 | 8,833.60 | 26.50 | 0.30% |
| SSE Composite Index | 3,641.91 | 6.78 | 0.19% |